Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2].
Ceci F, M.J. (2017). New radiopharmaceutical Markers for Matebolism and receptor. Berlino : Springer.
New radiopharmaceutical Markers for Matebolism and receptor
Ceci F;Fanti S
2017
Abstract
Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2].File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.